A pharmacokinetic study of Bekinda (Ondansetron) 12 mg for the treatment of treatment of diarrhea-predominant irritable bowel syndrome (IBS-D).

Trial Profile

A pharmacokinetic study of Bekinda (Ondansetron) 12 mg for the treatment of treatment of diarrhea-predominant irritable bowel syndrome (IBS-D).

Completed
Phase of Trial: Phase I

Latest Information Update: 18 Feb 2016

At a glance

  • Drugs Ondansetron (Primary)
  • Indications Irritable bowel syndrome
  • Focus First in man; Pharmacokinetics
  • Most Recent Events

    • 18 Feb 2016 New trial record
    • 11 Feb 2016 According to a RedHill Biopharma media release, PK profile of BEKINDA 12 mg when compared with BEKINDA 24 mg showed quivalent dose-adjusted bioavailability and dose-linearity between the two strengths.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top